HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivatives.

Abstract
The potent fibrinolytic enzyme, plasmin has numerous clinical applications for recannulizing vessels obstructed by thrombus. Despite its diminutive size, 91 kDa, success in the recombinant expression of this serine protease has been limited. For this reason, a truncated non-glycosylated plasmin variant was developed capable of being expressed and purified from E. coli. This mutated plasmin, known as δ-plasmin, eliminates four of the five kringle domains present on native plasmin, retaining only kringle 1 fused directly to the unmodified catalytic domain of plasmin. This study demonstrates that δ-plasmin exhibits similar kinetic characteristics to full length plasmin despite its heavily mutated form; KM = 268.78 ± 19.12, 324.90 ± 8.43 μM and Kcat = 770.48 ± 41.73, 778.21 ± 1.51 1/min for plasmin and δ-plasmin, respectively. A comparative analysis was also carried out to investigate the inhibitory effects of a range of benzamidine based small molecule inhibitors: benzamidine, p-aminobenzamidine, 4-carboxybenzamidine, 4-aminomethyl benzamidine, and pentamidine. All of the small molecule inhibitors, with the exception of unmodified benzamidine, demonstrated comparable competitive inhibition constants (Ki) for both plasmin and δ-plasmin ranging from Ki < 4 μM for pentamidine to Ki > 1000 μM in the case of aminomethyl benzamidine. This result further supports that δ-plasmin retains much of the same functionality as native plasmin despite its greatly reduced size and complexity. This study serves the purpose of demonstrating the tunable inhibition of plasmin and δ-plasmin with potential applications for the improved clinical delivery of δ-plasmin to treat various thrombi.
AuthorsNathan J Alves, Jeffrey A Kline
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 457 Issue 3 Pg. 358-62 (Feb 13 2015) ISSN: 1090-2104 [Electronic] United States
PMID25576865 (Publication Type: Comparative Study, Journal Article)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Antifibrinolytic Agents
  • Benzamidines
  • Mutant Proteins
  • Recombinant Proteins
  • Plasminogen
  • Fibrinolysin
Topics
  • Antifibrinolytic Agents (chemistry, pharmacology)
  • Benzamidines (chemistry, pharmacology)
  • Fibrinolysin (antagonists & inhibitors, chemistry, genetics)
  • Humans
  • Kinetics
  • Models, Molecular
  • Mutant Proteins (antagonists & inhibitors, chemistry, genetics)
  • Plasminogen (chemistry)
  • Protein Conformation
  • Protein Structure, Tertiary
  • Recombinant Proteins (chemistry, genetics)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: